Seeking Alpha

Shares of Targacept (TRGT -11%) take a hit today after the drug developer says that Phase II...

Shares of Targacept (TRGT -11%) take a hit today after the drug developer says that Phase II trials of TC-5619 - for the treatment of inattentive-predominant attention deficit/hyperactivity disorder - did not meet their primary endpoint. Quixotically, the trial results showed patients on a placebo consistently improved more than patients on TC-5619.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs